Skip to main content
Equibles

Barry Flannelly

Analyst

Commercial Lead

Board Member

Protara Therapeutics, Inc. (TARA)

Equibles does not estimate personal net worth.

About Barry Flannelly

Barry Flannelly is recorded as Analyst at Commercial Lead and Board Member at Protara Therapeutics, Inc. (TARA). The newest filing on record that lists Barry Flannelly as Board Member at Protara Therapeutics, Inc. (TARA) is dated April 28, 2026. Incyte Corp reported in an 8-K filed January 10, 2025 that Barry Flannelly retired as Executive Vice President, General Manager, North America, effective January 6, 2025. The proxy statement of Incyte Corp reports total compensation of $4,116,884 for Barry Flannelly in fiscal 2020, including a base salary of $480,542. Disclosed compensation is on record for 2 fiscal years. Barry Flannelly has spoken on 11 earnings calls across 1 company, most recently for Incyte Corp on February 13, 2024. Protara Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Barry Flannelly spoke on are classified in the Healthcare sector. Other leadership on record at Protara Therapeutics, Inc. includes Jesse Shefferman (CEO and Board Member), Luke Beshar (Chairman), Blaine Davis (CFO) and 7 others.

“On January 6, 2025, Barry P. Flannelly, Executive Vice President, General Manager, North America of Incyte Corporation (the "Company"), announced his retirement from the Company and stepped down from that role on that date, effective with the commencement of employment of his successor.”
Incyte Corp Form 8-K, filed January 10, 2025 · Read the filing

Barry Flannelly on recent calls

“In the fourth quarter, Jakafi net product revenue increased by 7% year-over-year to $695 million and saw an 8% growth for the full year, reaching $2.6 billion. The total number of patients rose by 6% in 2023, with growth observed across all indications.”
CFO, Incyte Corp Q4 FY2023 Earnings Call ·
“Patient demand for Jakafi was strong across all indications. New patient starts, which are a strong leading indicator for growth in future quarters, grew 8% year-on-year to reach an all-time high.”
CFO, Incyte Corp Q1 FY2023 Earnings Call ·
“In the fourth quarter, Jakafi net sales grew 9% year-over-year to $647 million and grew 13% for the full year to $2.4 billion. Total patient demand rose 7% in 2022, driven by an increase in new patients across all indications.”
CFO, Incyte Corp Q4 FY2022 Earnings Call ·
“The launch of Opzelura continues to be very successful with double-digit demand growth in atopic dermatitis and strong uptake in vitiligo. Net sales grew 130% quarter-over-quarter to reach $38 million, led by strong patient demand and broader reimbursement coverage for Opzelura.”
CFO, Incyte Corp Q3 FY2022 Earnings Call ·
“Starting with OPZELURA, the launch in atopic dermatitis continues to be strong, and we are very pleased with the progress that we have made across a number of important metrics.”
CFO, Incyte Corp Q2 FY2022 Earnings Call ·

Affiliation history

Company network

Leadership on record at Protara Therapeutics, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2020 Incyte Corp (INCY) $480,542 $4,116,884
2019 Incyte Corp (INCY) $458,438 $5,442,942

Recent activity